Real world data: additional source for making clinical decisions

R Mahajan - International Journal of Applied and Basic Medical …, 2015 - journals.lww.com
Though randomized clinical trials (RCTs) are considered gold standard for establishing
efficacy;[2] in general, RCTs use a standardized therapy in a selected group of patients and …

Real world data: Additional source for making clinical decisions

R Mahajan - International Journal of Applied and Basic Medical …, 2015 - ncbi.nlm.nih.gov
Though randomized clinical trials (RCTs) are considered gold standard for establishing
efficacy;[2] in general, RCTs use a standardized therapy in a selected group of patients and …

Real world data: Additional source for making clinical decisions.

R Mahajan - International Journal of Applied & Basic Medical …, 2015 - europepmc.org
International Society for Pharmacoeconomics and Outcome Research has defined real-
world data as everything that goes beyond what is normally collected in the phase III clinical …

[引用][C] Real world data: Additional source for making clinical decisions

R Mahajan - International journal of applied & basic …, 2015 - pubmed.ncbi.nlm.nih.gov

Real world data: Additional source for making clinical decisions

R Mahajan - International Journal of Applied and Basic …, 2015 - search.proquest.com
Real world data: Additional source for making clinical decisions Page 1 International Journal of
Applied and Basic Medical Research, May-Aug 2015, Vol 5, Issue 2 82 Real world data …

[PDF][PDF] Real world data: Additional source for making clinical decisions

R Mahajan - pdfs.semanticscholar.org
Though randomized clinical trials (RCTs) are considered gold standard for establishing
efficacy;[2] in general, RCTs use a standardized therapy in a selected group of patients and …

Real world data: Additional source for making clinical decisions.

R Mahajan - International Journal of Applied & Basic Medical …, 2015 - europepmc.org
International Society for Pharmacoeconomics and Outcome Research has defined real-
world data as everything that goes beyond what is normally collected in the phase III clinical …